Learn about side effects, uses, and more for Libtayo (cemiplimab-rwlc), ... Off-label drug use is when an FDA-approved drug is prescribed for a purpose other than what it’s approved for.

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

TARRYTOWN, N.Y., Nov. 5, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today provided an update on the ongoing Phase 3 development program evaluating Libtayo ® (cemiplimab ...

Libtayo® (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma Objective responses seen in 29% of patients with locally advanced basal cell ...

The approval is based on data from the randomized, open-label phase 3 EMPOWER-Lung1 trial (ClinicalTrials.gov: NCT03088540), which assessed Libtayo in 710 adults with advanced or metastatic NSCLC ...

Libtayo nabbed its first FDA green light in 2018 for advanced cutaneous squamous cell carcinoma. Two weeks ago, it added basal cell carcinoma to its label. It raked in sales of about $348 million ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for another indication. The drug has been approved in combination with ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo (R) (cemiplimab) for the first-line treatment of ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo (R) (cemiplimab) to treat adults with locally ...

Regeneron Pharmaceuticals (REGN 2.25%) and Sanofi (SNY 3.27%) announced last month that the U.S. Food and Drug Administration (FDA) had accepted their jointly developed cancer drug, Libtayo, for ...

Regeneron’s PD-1 inhibitor Libtayo was accepted for priority FDA review for the treatment of first-line locally advanced or metastatic non–small cell lung cancer (NSCLC) with PD-L1 expression ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) for another indication.